PPAR-γ has been shown to be dysregulated in the obese population [21], and since obesity is a known risk factor for breast cancer development, PPAR-γ activity may have a role in breast cancer inhibition. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.